Psoriatic Arthritis: A Review

Authors:

^*Farrouq Mahmood,¹ Philip Helliwell²

1. Rheumatology Specialist Registrar, Dewsbury District Hospital, North Kirklees, UK
2. Consultant and Senior Lecturer in Rheumatology, Faculty of Medicine and Health, University of Leeds, Leeds, UK
*Correspondence to [email protected]

Disclosure:

The authors have declared no conflicts of interest.

Received:

08.03.16

Accepted:

16.06.16

Citation:

EMJ Rheumatol. 2016;3[1]:114-117. DOI/10.33590/emjrheumatol/10313412. https://doi.org/10.33590/emjrheumatol/10313412.

Keywords:

Psoriatic arthritis (PSA), disease modifying anti-rheumatic drugs (DMARDs), biologics, the classification of psoriatic arthritis (CASPAR), dactylitis, arthritis mutilans, rheumatoid arthritis, tumour necrosis factor alpha (TNF-α)

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.